A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1
130
about 4.9 years
18+
7 sites in CO, MA, MD +4
What this study is about
This trial is testing a treatment called MGD024 for people with certain types of blood cancers that haven't responded to other treatments or have come back after treatment. The goal is to see if MGD024 is safe, how it affects the body, and if it can fight cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take MGD024
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number and types of adverse events (AEs), including serious adverse events (SAEs), and AEs leading to treatment discontinuation.
Secondary: Complete response rate, Mean area under the concentration-time curve (AUC), Median duration of response, Median progression free survival, Number of participants with AEs and SAEs occurring after administration of tocilizumab or etanercept for cytokine release syndrome (CRS), Number of participants with changes in cytokines or C-reactive protein after administration of tocilizumab or etanercept, Overall response rate, Overall survival
Oncology